Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected and asymptomatic chronic hepatitis virus B carriers at Bangladesh

Viral Immunology

Volumn 23, Issue 3, 2010, Pages 335-338

  Al Mahtab, Mamun ^a,d   Rahman, Salimur ^a,d   Fazle Akbar, Sheikh Mohammad ^b   Khan, Sakirul Islam ^c,d   Uddin, Helal ^d   Karim, Fazal ^e   Ahmed, Faroque ^e  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^b Shinagawa ku   (Japan)

^c BANGLADESH AGRICULTURAL UNIVERSITY   (Bangladesh)

^d Viral Hepatitis Foundation Bangladesh   (Bangladesh)

^e DHAKA MEDICAL COLLEGE   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; BANGLADESH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOMODULATION; LIVER INJURY; TREATMENT DURATION; VACCINATION; VIRUS IMMUNITY; BLOOD; HETEROZYGOTE; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER; METHODOLOGY; PATHOLOGY; VIRUS LOAD;

HEPATITIS B VIRUS;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BANGLADESH; CARRIER STATE; DNA, VIRAL; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; LAMIVUDINE; LIVER; VIRAL LOAD;

EID: 77954172716     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0104     Document Type: Article

References (10)

1. Al-Mahtab M, Rahman S, Akbar SM, Khan M, Fazal MK, and Kamal M: High HBV DNA, HBeAg positivity, and considerable necroinflammation in patients with incidentally- detected asymptomatic chronic HBV-infected individuals from Bangladesh. Hepatology 2008;48(Suppl):690A.
2. Betancourt AA, Delgado CA, Estévez ZC, et al.: Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007;11:394-401.
3. Ganem D and Prince AM: Hepatitis B virus infection- natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
4. Hoa PT, Huy NT, Thu LT, et al.: A randomized-controlled study investigating viral suppression and serological response following PreS1=PreS2=S vaccine therapy combined with lamivudine in HBeAg-positive chronic hepatitis B patients. Antimicrob Agents Chemother 2009;53:5134-5140.
5. Horiike N, Fazle Akbar SM, Michitaka K, et al.: In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-161.
6. Jung MC and Pape GR: Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50.
7. Kumar M, Sarin SK, Hissar S, et al.: Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376-1384.
8. Kumar M, Chauhan R, Gupta N, Hissar S, Sakhuja P, and Sarin SK: Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology 2009;136:1272-1280.
9. Lok AS: The maze of treatments for hepatitis B. N Engl J Med 2005;352:2743-2746.
10. Lok AS and McMohan BJ: Chronic hepatitis B. Hepatology 2007;45:507-539.